网站地图 联系我们搜索内部网English | 中国科学院
首页 所况简介 机构设置 科研队伍 科学研究平台 院地合作 党群园地 国际交流 博士后 研究生教育 信息公开
科研进展
成果报道
最新重要论文(影响因子PNAS及以上)
发表论文数据库
所级学术报告
科学成果
发表论文
专著
专利
获奖
专题
所史丛书
所庆专辑
建所50周年画册
现在位置:首页 > 科研进展 > 最新重要论文(影响因子PNAS及以上)
A tumor-targeted immune checkpoint blocker, PNAS, 22 Jul 2019
2019-07-22 | 【     】【打印】【关闭

PNAS, 22 July, 2019, DOI: https://doi.org/10.1073/pnas.1905646116

A tumor-targeted immune checkpoint blocker

Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz, Yu J. Cao, and Feng Wang

Abstract

To direct checkpoint inhibition to the tumor microenvironment, while avoiding systemic immune activation, we have synthesized a bispecific antibody [norleucine4, D-Phe7]-melanocyte stimulating hormone (NDP-MSH)-antiprogrammed cell death-ligand 1 antibody (αPD-L1) by conjugating a melanocyte stimulating hormone (α-MSH) analog to the antiprogrammed cell death-ligand 1 to (αPD-L1) antibody avelumab. This bispecific antibody can bind to both the melanocortin-1 receptor (MC1R) and to PD-L1 expressed on melanoma cells and shows enhanced specific antitumor efficacy in a syngeneic B16-SIY melanoma mouse model compared with the parental antibody at a 5 mg/kg dose. Moreover, the bispecific antibody showed increased infiltrated T cells in the tumor microenvironment. These results suggest that a tumor-targeted PD-L1-blocking bispecific antibody could have a therapeutic advantage in vivo, especially when used in combination with other checkpoint inhibitors.

文章链接:https://www.pnas.org/content/early/2019/07/11/1905646116

相关报道:http://www.ibp.cas.cn/kyjz/zxdt/201907/t20190708_5336488.html

 

评 论
          
版权所有:中国科学院生物物理研究所     京ICP备05002792号 京公网安备 110402500011 号
地址:北京市朝阳区大屯路15号(100101) 电话:010-64889872
意见反馈联系人:侯文茹 电子邮件:houwenru@ibp.ac.cn